Lung Cancer

Ramucirumab (Cyramza; Eli Lilly) is FDA-approved for 5 unique cancer indications.

Poziotinib demonstrates positive results for treatment-naïve patients with non-small cell lung cancer harboring HER2 exon 20 insertion mutations.

Nivolumab (Opdivo) plus platinum-doublet chemotherapy approved for the treatment of adult patients with resectable non–small cell lung cancer in the neoadjuvant setting.

Acceptance is based on CheckMate -816 trial results where the agency granted priority review status to the Bristol Myers Squibb drug and assigned a PDUFA goal date of July 13, 2022.

FDA to evaluate adagrasib for the treatment of patients with non–small cell lung cancer with tumors that have a KRAS G12C mutation.

All the participants were in the Beating Lung Cancer in Ohio study, which started before the COVID-19 pandemic.

Clinical benefits were seen across subgroups, including patients with squamous and non-squamous lung cancer subtypes, and regardless of PD-L1 levels.

The sBLA is reinforced by results from a randomized phase 3 trial that investigated cemiplimab-rwlc in combination with a physician’s choice of platinum-doublet chemotherapy compared to platinum-doublet chemotherapy alone.

The findings from the phase 3 KEYNOTE-091 trial mark the first positive study for pembrolizumab in adjuvant stage IB-IIIA non-small cell lung cancer.

Patients with EGFR exon 20 insertion mutation NSCLC account for approximately 1%-2% of NSCLC cases.

In the first quarter of 2022, Genprex expects to initiate its Acclaim-2 clinical trial to evaluate the treatment for individuals with histologically confirmed unresectable stage III or IV non–small cell lung cancer.

Telisotuzumab vedotin (Teliso-V, AbbVie) is an investigational antibody-drug conjugate that targets c-Met, a receptor tyrosine kinase that is overexpressed in tumors.

The Breakthrough Therapy Designation was granted based on data from the dose escalation portion of 2 expansion cohorts of a 3-cohort phase 1 study.

Commonly used medications may influence responses to checkpoint inhibitors among patients with cancer.

Since its initial approval in 2016 for urothelial carcinoma, atezolizumab has received FDA approval for an additional 5 types of carcinomas.

Advancements in genomic and mutational analysis show that up to 60% of adenocarcinomas and up to 50% to 80% of squamous cell carcinomas (SCC) have a known oncogenic driver mutation.

Fast track application is based on positive data in HER2 exon 20 insertion mutations in previously treated patients.

Tepotinib treats adult patients with metastatic non-small cell lung cancer harboring a mesenchymal epithelial transition exon 14 skipping alteration.

Although specialty therapies have the potential to help people live healthier lives, their cost and complexity can create distinct challenges.

Mobocertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that irreversibly binds to and inhibits EGFR exon 20 insertion mutations at lower concentrations than wild type (WT) EGFR.

The results of a study showed that non-Hispanic Black patients treated with immunotherapy had a 15% lower risk of death from non–small cell lung cancer than non-Hispanic white patients.

After 6 to 7 months, just 8 individuals contracted proven symptomatic SARS-CoV-2 infection with rapid favorable evolution, study results show.

Durvalumab is a human immunoglobulin G1 kappa monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80.

Pembrolizumab (Keytruda) can be used for multiple cancer types, including melanoma, non-small cell lung cancer, and head and neck squamous cell cancer.

The investigators said that the trial data showed potentially clinically meaningful improvements in both progression-free survival and overall survival in pre-specified subgroups of patients based on the baseline inflammatory biomarker, hs-CRP, as well as other biomarker-defined subgroups.